Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer For TPI 287 In Brain Cancer Indications

(MENAFN- Investor Brand Network) CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.

To view the full press release, visit

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company's website at .

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN13052025000224011066ID1109544182